252 related articles for article (PubMed ID: 27604789)
1. In vivo molecular profiling of human glioma using diffusion kurtosis imaging.
Hempel JM; Bisdas S; Schittenhelm J; Brendle C; Bender B; Wassmann H; Skardelly M; Tabatabai G; Vega SC; Ernemann U; Klose U
J Neurooncol; 2017 Jan; 131(1):93-101. PubMed ID: 27604789
[TBL] [Abstract][Full Text] [Related]
2. Diffusion kurtosis imaging combined with molecular markers as a comprehensive approach to predict overall survival in patients with gliomas.
Wang X; Li F; Wang D; Zeng Q
Eur J Radiol; 2020 Jul; 128():108985. PubMed ID: 32361603
[TBL] [Abstract][Full Text] [Related]
3. In Vivo Molecular Profiling of Human Glioma : Cross-Sectional Observational Study Using Dynamic Susceptibility Contrast Magnetic Resonance Perfusion Imaging.
Hempel JM; Schittenhelm J; Klose U; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Brendle C
Clin Neuroradiol; 2019 Sep; 29(3):479-491. PubMed ID: 29468261
[TBL] [Abstract][Full Text] [Related]
4. Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study.
Hempel JM; Brendle C; Bender B; Bier G; Kraus MS; Skardelly M; Richter H; Eckert F; Schittenhelm J; Ernemann U; Klose U
Eur J Radiol; 2019 Mar; 112():144-152. PubMed ID: 30777204
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
6. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
7. Histogram analysis of diffusion kurtosis imaging estimates for in vivo assessment of 2016 WHO glioma grades: A cross-sectional observational study.
Hempel JM; Schittenhelm J; Brendle C; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Klose U
Eur J Radiol; 2017 Oct; 95():202-211. PubMed ID: 28987669
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic algorithm for pathological evaluation of gliomas in a resource-constrained setting.
Jain S; Gupta P; Shankar KB; Singh R; Siraj F
J Cancer Res Ther; 2023; 19(3):562-566. PubMed ID: 37470575
[TBL] [Abstract][Full Text] [Related]
10. In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice.
Hempel JM; Schittenhelm J; Bisdas S; Brendle C; Bender B; Bier G; Skardelly M; Tabatabai G; Castaneda Vega S; Ernemann U; Klose U
J Neuroradiol; 2018 Feb; 45(1):32-40. PubMed ID: 28865921
[TBL] [Abstract][Full Text] [Related]
11. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of the diffusion kurtosis imaging and diffusion tensor imaging in grading gliomas, predicting tumour cell proliferation and IDH-1 gene mutation status.
Zhao J; Wang YL; Li XB; Hu MS; Li ZH; Song YK; Wang JY; Tian YS; Liu DW; Yan X; Jiang L; Yang ZY; Chu JP
J Neurooncol; 2019 Jan; 141(1):195-203. PubMed ID: 30414095
[TBL] [Abstract][Full Text] [Related]
13. Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study.
Hempel JM; Brendle C; Bender B; Bier G; Skardelly M; Gepfner-Tuma I; Eckert F; Ernemann U; Schittenhelm J
J Neurooncol; 2018 Sep; 139(2):373-381. PubMed ID: 29667086
[TBL] [Abstract][Full Text] [Related]
14. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
[TBL] [Abstract][Full Text] [Related]
15. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
16. [Correlation between loss of heterozygosity on chromosome 1p and 19q and expression of MGMT, p53 and Ki-67 proteins in gliomas].
Huang L; Jiang T; Yuan F; Li GL; Xu LX; Cui Y
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):752-8. PubMed ID: 22335907
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract][Full Text] [Related]
18. The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.
Tuononen K; Tynninen O; Sarhadi VK; Tyybäkinoja A; Lindlöf M; Antikainen M; Näpänkangas J; Hirvonen A; Mäenpää H; Paetau A; Knuutila S
Genes Chromosomes Cancer; 2012 Jan; 51(1):20-9. PubMed ID: 21922591
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models.
Figini M; Riva M; Graham M; Castelli GM; Fernandes B; Grimaldi M; Baselli G; Pessina F; Bello L; Zhang H; Bizzi A
Radiology; 2018 Dec; 289(3):788-796. PubMed ID: 30277427
[TBL] [Abstract][Full Text] [Related]
20. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma.
Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E
Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]